PAK7 mutations were found to be associated with tumor mutation burden, neoantigen load, copy number variation, CD8+ TILs, mutation rate in the DDR-related pathways, suggesting that PAK7 mutations could be a helpful biomarker for prediction of the immunotherapy efficacy in NSCLC patients (Zeng et al., 2022). Here, CD8A is linked to non-small cell lung carcinoma.